Capricor Therapeutics said 24-month HOPE 3 extension data showed Deramiocel reduced the measured outcome by 76% in patients who switched to treatment after a year on placebo. The update was presented at the 2026 World Muscle Society Congress.
published
Capricor Therapeutics said 24-month HOPE 3 extension data showed Deramiocel reduced the measured outcome by 76% in patients who switched to treatment after a year on placebo. The update was presented at the 2026 World Muscle Society Congress.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.